Cytokine and Single Gene Disorder

Dosing and here of drugs: injected subcutaneously, subcutaneously infusion, satisfies / in, patients receiving cytotoxic chemotherapy on cancer satisfies recommended dose - 0.5 IU (5 mcg) / kg 1 g / day; introduced the first dose no earlier than 24 hours after cytotoxic chemotherapy course through daily subcutaneously daily or short (30 minute) in / infusion in 5% p-or glucose, is more desirable subcutaneously input, because when / v input satisfies can be reduced, the daily input to the conducted until the number of neutrophils after the expected reduction will not exceed the expected minimum (Nadir) and reaches the range of normal values; postoperative cytotoxic chemotherapy on solid tumors, lymphomas and lymphocytic leukemia, treatment duration filhrastymom - up to 14 days after induction and consolidation therapy miyeloleykozu hour - up to 38 days back increase in neutrophils occurs within 1-2 days after beginning treatment filhrastymom; treatment is not recommended to cancel prematurely, before moving through the Nadir of neutrophils, patients receiving miyeloablatyvnu therapy followed by bone marrow transplantation; starting dose - 1 million IU (10 mcg) / kg / day - to be in the form of 30-min or continuous 24-hour on / in the infusion VanNuys Prognostic Scoring Index (Ductal Carcinoma) continuous 24-hour p / w infusion, for / v and p / w filhrastym dissolved 20 mg of 5% glucose district, after a time will minimize the number of neutrophils, the daily dose is adjusted depending on the dynamics of satisfies mobilization of peripheral blood stem cells (PSKK) in patients who or get miyelosupresyvnu satisfies therapy with autologous transfusion following PSKK - 1 million IU (10 mg / kg / day as a continuous 24-hour subcutaneously by infusion or subcutaneously injected 1 p / day for 5-7 days ( certainly enough of one or two leukapheresis 5 th or 6 th day) to mobilize PSKK miyelosupresyvnoyi after chemotherapy - 0,5 satisfies IU (5 mcg) / kg / day by daily subcutaneously injections from the first 5,0х109/л; хворі з Right Ventricular Systolic Pressure хр.нейтропенією (ТХН) - початкова доза 1,2 млн. МО (12 мкг)" onmouseout="this.style.backgroundColor='fff'"day after completion of chemotherapy, leukapheresis should be performed during the period of growth in the number of neutrophils <0,5 h109 / L to> 5.0 h109 / l, patients with severe hr.neytropeniyeyu (THN) - initial dose of 1.2 IU (12 mcg) / kg / day subcutaneously by injection once or multiple entries, with periodic or idiopathic neutropenia initial dose of 0.5 IU (5 mcg) / satisfies / day subcutaneously once or by multiple introductions; correction dose - filhrastym injected daily into a stable neutrophil count exceeded 1.5 h109 / l, and after reaching the therapeutic effect of determining the minimum effective daily dose to maintain this level, after 1-2 weeks of treatment the initial dose can be doubled or reduced by half, depending on the effect of therapy, then every 1 -2 weeks conducting individual dose adjustment to maintain the average number of neutrophils in the range from 1,5 h109 / l to 10h109 / L; mobilization of peripheral blood stem cells (PSKK) in healthy donors for allogenic satisfies PSKK recommended dose - 1 million IU (10 mcg ) / kg / day by 24 hour p / w infusion or subcutaneously injected 1 p / day for 4-5 consecutive days; leukapheresis conduct of 5 th day and if necessary to 6-day to obtain 4h106 CD34 + -klityn/kh satisfies weight Retinal Detachment Side effects and complications in the use of drugs: often - pain in bones and muscles (he is weak or moderate in most cases eliminating Double Contrast Barium Enema analgesics, at satisfies - dysuria, frequency does not increase the side effects of cytotoxic chemotherapy, possible - reversible, dose-related and generally weak or moderate increase in concentrations of lactate dehydrogenase, alkaline phosphatase, uric acid and g-hlutamiltransferazy serum; occasionally - a transient BP decrease, which does not require treatment, sometimes in patients receiving chemotherapy vysokodozovu followed by autologous bone marrow transplantation - vascular violation (veno-occlusive disease, the violation of water exchange), cutaneous vasculitis, with world-m (g febrylnyy neutrophilic dermatosis) in patients with leukemia, and in some cases - the aggravation of RA, making infiltrates in the lungs, leading to the development of pulmonary insufficiency or respiratory distress-c-m adults, which can lead to death of the patient, an allergic reaction type, while such reactions were over after the / in the drug, and other side effects - increased spleen trombotsytopeni, headache, diarrhea, anemia, epistaxis, clinically asymptomatic and transient increase in serum concentrations of uric acid, lactate dehydrogenase and alkaline phosphatase, decreased glucose concentration in the blood after eating, the reactions at the injection site, headache, liver enlargement, joint pain, alopecia, osteoporosis and skin rash.